Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials

Vaccine

Volumn 28, Issue 50, 2010, Pages 7993-8000

  Torresi, Joseph ^a,b   McCarthy, Karen ^c,e   Feroldi, Emmanuel ^d   Méric, Claude ^d  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Acambis   (United States)

^d SANOFI PASTEUR   (France)

^e PRA HEALTH SCIENCES   (United States)

Author keywords

Attenuated vaccines; Clinical trial, phase 3; Japanese encephalitis vaccines

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; JE CV; JE CV VACCINE; LIVE VACCINE; MBD JE VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SWELLING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; ENCEPHALITIS, JAPANESE; FEMALE; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 78650253263     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.035     Document Type: Article

References (33)

1. Tsai T.F. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000, 18(Suppl. 2):1-25.
2. World Health Organization Japanese encephalitis vaccines. Wkly Epidemiol Rec 2006, 81(34-35):331-340.
3. Halstead S.B., Tsai T.F. Japanese encephalitis vaccine. Vaccines 2004, 919-958. Saunders, Philadelphia. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
4. Hanna J., Barnett D., Ewald D. Vaccination against Japanese encephalitis in the Torres Straight. Commun Dis Intel 1996, 20(8):188-190.
5. Hoke C.H., Nisalak A., Sangawhipa N., Jatanasen S., Laorakapongse T., Innis B.L., et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988, 319(10):608-614.
6. Global advisory committee on vaccine safety, 9-10 June 2005. Wkly Epidemiol Rec 2005, 80(28):242-247.
7. Hennessy S., Liu Z., Tsai T.F., Strom B.L., Wan C.M., Liu H.L., et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996, 347(9015):1583-1586.
8. Tandan J.B., Ohrr H., Sohn Y.M., Yoksan S., Ji M., Nam C.M., et al. Single dose of SA14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 2007, 25(27):5041-5045.
9. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007, 370(9602):1847-1853.
10. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A 2006, 103(17):6694-6699.
11. Beasley D.W., Li L., Suderman M.T., Guirakhoo F., Trent D.W., Monath T.P., et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 2004, 22(27-28):3722-3726.
12. Dean C.H., Alarcon J.B., Waterston A.M., Draper K., Early R., Guirakhoo F., et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Hum Vaccine 2005, 1(3):106-111.
13. Guirakhoo F., Zhang Z.X., Chambers T.J., Delagrave S., Arroyo J., Barrett A.D., et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 1999, 257(2):363-372.
14. Monath T.P., Soike K., Levenbook I., Zhang Z.X., Arroyo J., Delagrave S., et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 1999, 17(15-16):1869-1882.
15. Monath T.P., Levenbook I., Soike K., Zhang Z.X., Ratterree M., Draper K., et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol 2000, 74(4):1742-1751.
16. Jones T. A chimeric live attenuated vaccine against Japanese encephalitis. Expert Rev Vaccines 2004, 3(3):243-248.
17. Monath T.P., McCarthy K., Bedford P., Johnson C.T., Nichols R., Yoksan S., et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002, 20(7-8):1004-1018.
18. Monath T.P., Guirakhoo F., Nichols R., Yoksan S., Schrader R., Murphy C., et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003, 188(8):1213-1230.
19. Hombach J., Solomon T., Kurane I., Jacobson J., Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005, 23(45):5205-5211.
20. Hombach J., Kurane I., Wood D. Arguments for live flavivirus vaccines. Lancet 2004, 364(9433):498-499.
21. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28(3):632-649.
22. Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 2000, 18(Suppl. 2):26-32.
23. Tsarev S.A., Sanders M.L., Vaughn D.W., Innis B.L. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 2000, 18(Suppl. 2):36-43.
24. Ali A., Igarashi A. Antigenic and genetic variations among Japanese encephalitis virus strains belonging to genotype 1. Microbiol Immunol 1997, 41(3):241-252.
25. Wills M.R., Singh B.K., Debnath N.C., Barrett A.D. Immunogenicity of wild-type and vaccine strains of Japanese encephalitis virus and the effect of haplotype restriction on murine immune responses. Vaccine 1993, 11(7):761-766.
26. Wills M.R., Sil B.K., Cao J.X., Yu Y.X., Barrett A.D. Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area. Vaccine 1992, 10(12):861-872.
27. Poland J.D., Calisher C.H., Monath T.P., Downs W.G., Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981, 59:895-900.
28. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccine 2006, 2(2):60-67.
29. McGee C.E., Lewis M.G., Claire M.S., Wagner W., Lang J., Guy B., et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis 2008, 197(5):693-697.
30. Pugachev K.V., Schwaiger J., Brown N., Zhang Z.X., Catalan J., Mitchell F.S., et al. Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE). Vaccine 2007, 25(37-38):6661-6671.
31. Chokephaibulkit K., Sirivichayakul C., Thisyakorn U., Sabchareon A., Pancharoen C., Bouckenooghe A., Gailhardou S., Boaz M., Feroldi E. Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2- to 5-year-olds and Naive 12- to 24-month-olds. Multicenter Randomized Controlled Trial. The Pediatric Infectious Disease Journal 2010, 29(12). [Epub ahead of print. Sep 17].
32. Tauber E., Kollaritsch H., von Sonnenburg F., Lademann M., Jilma B., Firbas C., et al. Randomised, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008, 198(4):493-499.
33. Bhatt T.R., Crabtree M.B., Guirakhoo F., Monath T.P., Miller B.R. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg 2000, 62(4):480-484.